Tag Archives: Akebia Therapeutics

Mizuho Securities Sticks to Its Buy Rating for Akebia Therapeutics

Mizuho Securities analyst Difei Yang maintained a Buy rating on Akebia Therapeutics (NASDAQ: AKBA) today and set a price target of $24. The company’s shares closed yesterday at $13.52. According to TipRanks.com, Yang is a 5-star analyst with an average

Mizuho Securities Releases a Buy Rating on Akebia Therapeutics

Mizuho Securities analyst Difei Yang assigned a Buy rating to Akebia Therapeutics (NASDAQ: AKBA) today and set a price target of $24. The company’s shares closed yesterday at $14.45. Yang noted: “We had a chance to catch up with CEO

H.C. Wainwright Issues a Buy Rating on Akebia Therapeutics

In a report released today, Ed Arce from H.C. Wainwright assigned a Buy rating to Akebia Therapeutics (NASDAQ: AKBA), with a price target of $24. The company’s shares closed yesterday at $14.24. According to TipRanks.com, Arce is a 5-star analyst

RBC Capital Remains a Hold on Akebia Therapeutics

In a report released today, Nicholas Keher from RBC Capital reiterated a Hold rating on Akebia Therapeutics (NASDAQ: AKBA), with a price target of $17. The company’s shares opened today at $17.82. According to TipRanks.com, Keher is a 1-star analyst

H.C. Wainwright Keeps Their Buy Rating on Akebia Therapeutics

In a report released today, Ed Arce from H.C. Wainwright reiterated a Buy rating on Akebia Therapeutics (NASDAQ: AKBA), with a price target of $24. The company’s shares closed yesterday at $13.62. According to TipRanks.com, Arce is a 5-star analyst

Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (NASDAQ: AKBA) and Shire (NASDAQ: SHPG)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akebia Therapeutics (NASDAQ: AKBA) and Shire (NASDAQ: SHPG) with bullish sentiments. Akebia Therapeutics (NASDAQ: AKBA) Aegis Capital analyst Difei Yang reiterated a